Vertex Pharmaceuticals, Inc. (VRTX)
442.96
-3.87
(-0.87%)
USD |
NASDAQ |
Jun 08, 16:00
442.89
-0.07
(-0.02%)
Pre-Market: 08:43
Vertex Pharmaceuticals Research and Development Expense (Quarterly) : 961.60M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 1.420B |
| Biogen, Inc. | 471.10M |
| CRISPR Therapeutics AG | 66.37M |
| Halozyme Therapeutics, Inc. | 25.56M |
| Gilead Sciences, Inc. | 1.354B |